Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer
Küçük Resim Yok
Tarih
2009
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Pensiero Scientifico Editor
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Aims and background. It has been appreciated for some time that the lack of detection of ovarian cancer at clinical and pathological (second-look laparotomy) evaluation is not synonymous with cure. The goal of this study was to define clinical risk factors for recurrence after complete pathological response to postoperative chemotherapy in patients with epithelial ovarian cancer. Methods. Fifty-seven patients who met the inclusion criteria of our study were evaluated. The characteristics (age, menopausal status, histological subtype, tumor grade, presence of ascites at diagnosis, type of omentectomy, FIGO stage, and residual tumor volume after primary surgery) of patients with and those Without tumor recurrence were compared. Results. The median follow-up was 52 months (range, 15-142 months). The overall survival rates of the patients were 100%, 96%, and 87% at 1, 3 and 5 years, respectively At the time of the study analysis, 21 of 57 (37%) patients had recurrent disease. The median time to recurrence was 16 months. Recurrences were most frequent in the pelvis and abdominal cavity (38%). Age, menopausal status, stage at diagnosis, and residual tumor volume after initial surgery were significantly related to the risk of recurrence in univariate analysis (P = 0.039, 0.038, 0.004, and 0.000, respectively). Residual tumor volume after initial surgery-was found to be the only significant independent prognostic factor (P = 0.049, HR: 0.16, 95% CI: 0.02-0.99). Conclusion. We believe it is necessary to conduct randomized studies on this issue because insight into predictors of recurrence after pathological complete response to postoperative chemotherapy could be used to select patients for trials of consolidation therapy.
Açıklama
Anahtar Kelimeler
Ovarian Cancer, Negative Second-Look Laparotomy, Recurrence, Negative 2nd-Look Laparotomy, Gynecologic-Oncology-Group, Intraperitoneal Cisplatin, Phase-Iii, Survival, Paclitaxel, Platinum, Carcinoma, Surgery, Trial
Kaynak
Tumori
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
95
Sayı
2
